Acetazolamide-Associated Acute Kidney Injury in Critically Ill Pediatric Patients
| Autor: | Brady S. Moffett, Ayse Akcan Arikan, Mahmood Khichi, Kelli Kulik |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Creatinine business.industry Incidence (epidemiology) medicine.medical_treatment Clinical Investigations 030232 urology & nephrology Acute kidney injury Renal function Retrospective cohort study medicine.disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Internal medicine Pediatrics Perinatology and Child Health medicine Pharmacology (medical) 030212 general & internal medicine Renal replacement therapy business Acetazolamide Kidney disease medicine.drug |
| Zdroj: | J Pediatr Pharmacol Ther |
| ISSN: | 1551-6776 |
| DOI: | 10.5863/1551-6776-26.5.467 |
| Popis: | OBJECTIVE Our objective was to determine the incidence and risk factors for intravenous acetazolamide-associated acute kidney injury (AKI).METHODS We utilized a retrospective cohort study including patients RESULTS A total of 868 patients met study criteria (male 55.8%, median age 0.66 years [IQR 0.19, 3.0 years]). Intravenous acetazolamide was administered at 5.1 ± 2.8 mg/kg/dose for a median of 4 doses (IQR 2, 6). Median baseline SCr was 0.28 mg/dL (IQR 0.22, 0.37), corresponding to a creatinine clearance of 115 ± 55 mL/min/1.73 m2. Acute kidney injury occurred in 26.8% (n = 233) of patients (stage I = 20.1%, stage II = 3.7%, stage III 3.1%), and no patients received renal replacement therapy. An ordinal logistic regression model identified an increased odds of AKI with cyclosporine, ethacrynic acid, and piperacillin-tazobactam administration.CONCLUSIONS Acute kidney injury occurs frequently in critically ill pediatric patients receiving intravenous acetazolamide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|